![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 13 of 13. This is the beginning of the thread.
Posted by Jeroen on August 14, 2008, at 9:50:06
Bifeprunox not approved, it was a 3rd generation class like Abilify, now why on earth didnt they approve this ? i have read nausea side effect is worse on it
Posted by Hygieia's Bowl on August 14, 2008, at 10:34:36
In reply to Bifeprunox not approved, posted by Jeroen on August 14, 2008, at 9:50:06
> Bifeprunox not approved, it was a 3rd generation class like Abilify, now why on earth didnt they approve this ?
From 2007 regarding US FDA:
--- The U.S. Food and Drug Administration informed Solvay and its partner Wyeth Pharmaceuticals (WYE.N: Quote, Profile, Research, Stock Buzz) that efficacy data in tests of the drug -- tipped to be a blockbuster -- were not yet sufficient to allow for approval of the drug.
Furthermore, the FDA asked for further information about the drug and more details about the death of a participant in the trials.
"The Agency also requested further information regarding human metabolism of bifeprunox, and information regarding a complex case of a patient who died while participating in one of the trials," Solvay said in a statement. ---
Just giving FYI that's a year old....
Posted by Jeroen on August 14, 2008, at 10:44:17
In reply to Re: Bifeprunox not approved » Jeroen, posted by Hygieia's Bowl on August 14, 2008, at 10:34:36
thats so sad
Posted by Marty on August 14, 2008, at 12:12:32
In reply to Re: Bifeprunox not approved, posted by Jeroen on August 14, 2008, at 10:44:17
"along with SLV313, aripiprazole and SSR-181507 combines minimal D2 receptor agonism with 5-HT receptor agonism.[1]"
There's other drugs in the pipeline that works the same way Bifeprunox does. And that fact should have weighted in when the FDA refused to approve it.
Didn't searched it out, but I think the way it work as an partial agonist (vs antagonist) is that it stimulate the receptor to a less extend that the endogenous neurotransmitter (dopamine & serotonin) and so when they occuping the receptor the endogenous can't: they are competitive and the net effect is less stimulation than without the med at those receptor BUT somehow more than other antagonistic antipsychotics. When I say 'more' I think it should have something to do with what I would call the "Carrier Signal" or "No activity level".. I dont know the scientific term for that. But let's say those meds make sure you don't have too much dopaminergic (D2) activity but always a little.
Very interesting stuff! I should research this as I'm sure I'm partly wrong about the "Carrier Signal" thing. It should have something to do with LTP or better/constant very weak projection improvement that does the difference for schizophrenic.
If someone knows better than me I'd like to have an explanation.
/\/\arty
Posted by Phillipa on August 14, 2008, at 12:24:51
In reply to Re: Bifeprunox not approved » Jeroen, posted by Marty on August 14, 2008, at 12:12:32
Don't know anymore but the latest addition to google. Phillipa
Phase III Europe; rejected by FDA in USFull specifications
--------------------------------------------------------------------------------Bifeprunox mesilate is a novel atypical antipsychotic agent under development by Solvay Pharmaceuticals as a treatment for schizophrenia and potentially conditions such as bipolar disorder.
Solvay and Lundbeck, its European marketing partner, had hoped to file for regulatory approval in Europe in 2006, with launch to follow in 2007. However, they now plan additional clinical work to strengthen the registration dossier and filing is not now expected before 2008.
In the US, meanwhile, Solvay and marketing partner Wyeth filed for regulatory approval with the FDA in October 2006. In August 2007, the companies received the disappointing news that their NDA for bifeprunox as a treatment for schizophrenia had been rejected.
The FDA expressed concerns about both the efficacy and safety of bifeprunox. Subsequently, Wyeth decided to pull out of the agreement and all North American rights to bifeprunox have now been returned to Solvay.
DOPAMINE PARTIAL AGONISTS REPRESENT A NEW CLASS OF ATYPICALS
The first generation of atypical antipsychotic drugs, which entered clinical practice over a decade ago, share the common property of dopamine D2 receptor antagonism.This mode of action is believed to be the primary pharmacological mechanism by which antipsychotic drugs ameliorate the positive, psychotic symptoms of schizophrenia.
Bifeprunox differs from first-generation atypical antipsychotics in that it acts as a partial D2 agonist. This property is shared by aripiprazole, a drug already marketed in Europe and the US for treatment of schizophrenia.
"All North American rights to bifeprunox have now been returned to Solvay."In contrast to D2 receptor antagonism, partial D2 agonism is believed to decrease dopamine activity in an overactive dopamine system while simultaneously increasing dopamine activity in regions of the brain where dopaminergic activity is too low.
By blocking overstimulated receptors and stimulating underactive ones, partial D2 agonists act as dopamine stabilisers.
In common with aripiprazole, bifeprunox also acts as a serotonin, 5-HT1A agonist. This property may contribute to efficacy against the negative symptoms of schizophrenia and reduce the likelihood of extrapyramidal symptoms (EPS).
This new class of atypical antipsychotic drugs, sometimes described as next-generation antipsychotics, is seen as an attractive treatment option for schizophrenia and potentially the acute manic phase of bipolar disorder.
INCREASING TREATMENT OPTIONS
Despite an expanding range of antipsychotic drugs, which have greatly improved treatment prospects for patients with schizophrenia, there remain significant treatment gaps. New antipsychotic drugs are needed with broader efficacy to treat patients unresponsive to current agents.Although the atypical antipsychotics offer improved safety and tolerability over conventional typical antipsychotics, especially with respect to EPS, drug safety is still an issue. Significant weight gain leading to metabolic disturbances (diabetes, heart disease), sexual dysfunction, hyperprolactinaemia, and cardiotoxicity are unwelcome side effects associated with some currently used atypical drugs.
Poor tolerability leads to poor treatment compliance and risk of relapse. Thus, there is a need for antipsychotics with improved safety and tolerability to improve compliance and outcome.
A placebo-controlled, dose-finding phase II trial in patients with schizophrenia showed that bifeprunox was both efficacious and well tolerated. Importantly, treatment with bifeprunox did not appear to cause some of the side effects seen with other atypicals agents in routine use, such as weight gain, hyperprolactinaemia and cardiotoxicity. Thus, in addition to a low incidence of EPS, similar to placebo, other benefits that may arise from clinical use of bifeprunox include:
No weight gain
No increase in prolactin levels
No adverse effect on blood lipids
No adverse effects on blood glucose levels
No QTc prolongation
If these promising findings are confirmed in the larger phase III trials now underway then bifeprunox is likely to be well received by the market."Bifeprunox differs from first-generation atypical antipsychotics in that it acts as a partial D2 agonist."WYETH ENDS PARTNERSHIP WITH SOLVAY
While Lundbeck secured worldwide development and marketing rights to bifeprunox outside Canada, Japan, Mexico and the US, Solvay had forged a partnership with Wyeth for the key US market. The co-development and marketing agreement between the two companies, which was signed in April 2004, focused on four of Solvay's investigational antipsychotic drugs: bifeprunox, SLV-310, SLV 313 and SLV-314.
Wyeth's decision to end the partnership with Solvay for bifeprunox and the other compounds arose from the FDA decision to reject bifeprunox and the belief that there was insufficient commercial value in the product for the two companies to share. All development and commercialisation rights in North America for bifeprunox, as well as global rights for the other compounds, have been returned to Solvay.
MARKETING COMMENTARY
Affecting around 1% of the general population, schizophrenia is a severe and debilitating mental illness. Antipsychotic drugs are the cornerstone of the management of schizophrenia and are designed to address the core symptoms of the illness, which include positive, negative, cognitive and affective symptoms.
Bifeprunox is one four antipsychotic drugs currently in advanced-stage development for treatment of schizophrenia. Analysts had believed that of the four, bifeprunox was the most likely to succeed, given its promising efficacy and side-effect profile.
However, this is now in doubt given its failure to secure FDA approval, which stemmed largely from the drug's inability to perform as well or better than existing antipsychotic drugs. Physicians are unlikely to switch patients from a drug that is working to one that may not work as well.
In the US six atypical agents currently compete for a share of the antipsychoti
Posted by B2chica on August 14, 2008, at 13:20:07
In reply to Bifeprunox not approved, posted by Jeroen on August 14, 2008, at 9:50:06
D@mn.
i just found out about this med and was reading it then came here and saw your post. i was getting really excited about it. seeing the lack of bad SE.
i would gladly switch off zyprexa to give it a try.it seems the meds effecting dopamine are the ones that work better for me (AP)
and was hoping this one would work for me.d@mn....d@mn
*****************were you the one that mentioned invega?
was someone using it? i can't remember
but have any info on that one?b2c.
Posted by B2chica on August 14, 2008, at 13:22:37
In reply to Re: Bifeprunox not approved » Jeroen, posted by B2chica on August 14, 2008, at 13:20:07
nevermind, i just saw it was a metabolite of risperidone and when i was on that it did nothing for me...like a sugar pill.
Posted by Jeroen on August 14, 2008, at 13:26:42
In reply to Re: Bifeprunox not approved » Jeroen, posted by B2chica on August 14, 2008, at 13:20:07
http://www.dr-bob.org/babble/20070730/msgs/773005.html
about invega users or just do a search dr-bob.org with invega in the search box
Posted by Jeroen on August 14, 2008, at 13:30:48
In reply to Re: Bifeprunox not approved » B2chica, posted by B2chica on August 14, 2008, at 13:22:37
have you tryed SeroQuel, it worked a short while for me only low dose 100 mg twice a day
Posted by B2chica on August 14, 2008, at 14:22:10
In reply to Bifeprunox not approved, posted by Jeroen on August 14, 2008, at 9:50:06
but there is another one called Fiapta(Iloperidone)? i'm not sure where its at but last i saw was Phase III.
Posted by B2chica on August 14, 2008, at 14:23:44
In reply to to B2chica, posted by Jeroen on August 14, 2008, at 13:30:48
i did and it worked great for about a month then i got really bad cognitive blunting. its like i'd forget how to use a computer (and i'm in IT)
Posted by Jeroen on August 14, 2008, at 14:31:25
In reply to Re: to B2chica » Jeroen, posted by B2chica on August 14, 2008, at 14:23:44
what are you taking right now then?
Posted by B2chica on August 14, 2008, at 15:06:30
In reply to Re: to B2chica, posted by Jeroen on August 14, 2008, at 14:31:25
just zyprexa, topomax and ritalin. i have a bottle of trazadone that i was taking, but i just upped my zprexa cuz my depression was getting bad again and i dont need the added sleepiness.
zyprexa mostly helps. but it only gets me to sea level, doesn't quite keep me afloat. so i need an AD or something so that i can actually smile once and a while.but i must say zyprexa is my life line. several times now its rode in and saved my life. its just not quite enough.
also it makes me so tired in the morning that i'm ALWAYS late to work, no matter HOW hard i try.the problem is most ssri (SNRI's) make me manic.
last trial was just a nightmare so i'm taking a break for now and just riding out the depression (for once not totally suicidal) and soon going to try something else.
i've narrowed it to pristiq or celexa.
but man i wish something else would come out.i think zyprexa works for me because it's the only one that targets D1 receptor.
of course it could just be the combination of receptors it effects also, who knows.
but i need to add something.best wishes to you J.
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.